EI
PTCT icon

EAM Investors’s PTC Therapeutics PTCT Stock Holding History

EAM Investors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-71,735
Closed -$5.45M – 357
2025
Q4 		$5.45M Buy
+71,735
New +$5.21M 0.61% 51
2015
Q2 		– Sell
-17,158
Closed -$1.04M – 364
2015
Q1 		$1.04M Sell
17,158
-53,715
-76% -$3.28M 0.12% 298
2014
Q4 		$3.67M Buy
70,873
+1,319
+2% +$58.1K 0.51% 43
2014
Q3 		$3.06M Sell
69,554
-39,790
-36% -$1.24M 0.62% 17
2014
Q2 		$2.86M Buy
+109,344
New +$2.34M 0.54% 26

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM Investors's PTCT Position: Q1 2026 in Review

EAM Investors sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 71,735 shares — an estimated $5.45M sold.

EAM Investors first reported a position in PTCT in Q2 2014 and held it in 5 quarters. The position peaked at $5.45M in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • EAM Investors reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 71,735 PTC Therapeutics shares in Q1 2026, an estimated $5.45M.
  • EAM Investors first reported a position in PTC Therapeutics in Q2 2014 and held it in 5 quarters.
  • EAM Investors's PTC Therapeutics position peaked at $5.45M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.